You are here


Original articles

Majzoub K, Hafirassou ML, Meignin C, Goto A., Marzi S., Fedorova A., Verdier Y, Vinh J., Hoffmann JA, Martin F., Baumert TF#, Schuster C*#, Imler JL*#. The ribosomal protein RACK1 is a specific host factor required for IRES-mediated translation of fly and human viruses. Cell, 2014, 159(5), 1086-95. *Corresponding authors, #co-senior authors.

Xiao F*, Fofana I*, Thumann C, Mailly L, Alles R, Robinet E, Meyer N, Schaeffer M, Habersetzer F, Doffoël M, Leyssen P, Neyts J, Zeisel MB, Baumert TF. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut, 2014, 64, 483-94.*Authors contributed equally.

Duong FHT*, Trincucci G*, Boldanova T, Calabrese D, Campana B, Krol I, Durand SC, Heydmann L, Zeisel MB, Baumert TF, Heim MH. Hepatic IFN- receptor 1 expression is induced in chronic hepatitis C and correlates with IFN-3 minor alleles and with non-response to IFN-α therapies. J. Exp. Med., 2014, 211, 857-68. *Authors contributed equally.

Douam F, Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D. Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology, 2014, 59, 776-88.

Leboeuf C*, Mailly L*, Wu T*, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E. In vivo proof-of-concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells. Mol. Ther., 2014, 22, 634-44. *Authors contributed equally.

Xiao F*, Fofana I*, Heydmann L, Barth H, Soulier E, Habersetzer F, Doffoël M, Bukh J, Patel AH, Zeisel MB, Baumert TF. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PloS Pathogens, 2014, 10, e1004128. *Authors contributed equally.

Mertz D, Affolter-Zbaraszczuk C, Barthès J, Cui J, Caruso F, Baumert TF, Voegel JC, Ogier J, Meyer F. Templated assembly of albumin-based nanoparticles for simultaneous gene silencing and magnetic resonance imaging. Nanoscale, 2014, 6, 11676-80.

Leboeuf C, Roser-Schilder J, Lambotin M, Durand S, Wu T, Fauvelle C, Su B, Bole-Richard E, Deschamps M, Ferrand C., Tiberghien P, Pessaux P, Baumert TF, Robinet E. Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes : an in vitro proof-of-concept. Gene Ther., 2014, 22, 172-80.

Habersetzer F, Moenne-Loccoz R, Meyer N, Schvoerer E, Simo-Noumbissie P, Dritsas S, Baumert TF, Doffoël M. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. Liver Int., 2014, 35, 130-9.

Lefèvre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C. Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein E. PLoS One, 2014, 9, e95550.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert T, Duverlie G, Séron K, Penin F, Dubuisson J. Identification of conserved residues in HCV envelope glycoprotein E2 modulating virus dependence on CD81 and SRB1 entry factors. J. Virol., 2014, 88, 10584-97.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese M, Zeisel M, Nicosia A, Baumert T, Kaderali L, Pietschmann T. Role of the hypervariable region 1 (HVR1) for the interplay of hepatitis C virus with entry factors and lipoproteins. J. Virol., 2014, 88, 12644-55.

King LY, Johnson KB, Zheng H, Weil L, Gudewicz T, Hoshida T, Corey KE, Ajayi T, Ufere N, Baumert TF, Chan AT, Tarabe KK, Fuchs BC, Chung RT. Host genetics predict clinical deterioration in HCV related cirrhosis. PLoS One, 2014, 9(12):e114747 doi:10.1371/journal.pone.0114747.
Carbajo-Lozova J, Ma-Lauer Y, Malesevic M, Theuerkorn M, Kahlert V, Prell E, Von Brunn B, Muth D, Baumert TF, Drosten C, Fischer G, Von Brunn A. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus. Res., 2014, 184, 44-53.

Piardi T, Sommacale D, Baumert T, Mutter D, Marescaux J, Pessaux P. Laparoscopic resection for hepatocellular carcinoma: comparison between Middle Eastern and Western experience. Hepatobiliary Surg. Nutr., 2014, 3, 60-72.

Reviews, editorials etc.

Chung RT, Baumert TF. "Curing Chronic Hepatitis C — The Arc of a Medical Triumph. N. Engl. J. Med., 2014, 370, 1576-8.

Mailly L, Zeisel MB, Baumert TF. Genetically humanized mice recapitulate the entire hepatitis C virus life cycle. J. Hepatol., 2014, 60, 671-3.

Fauvelle C, Felmlee DJ, Baumert TF. Unraveling hepatitis C virus structure. Cell Res., 2014, 24, 385-6.

Verrier ER, Gack MU, Baumert TF. cGAS, innate immune responses and viral hepatitis. Hepatology, 2014, 60, 1098-100.

Tawar RG, Mailly L, Baumert TF. A new HCV mouse model on the block. Cell. Res., 2014, 24, 1153-4.

Baumert T, Fauvelle C, Chen D, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J. Hepatol., 2014, 61(S1), S34-S44.

Felmlee DJ, Schuster C, Baumert TF. A new tool for the study of hepatitis C virus genotype 3 and its associated liver disease biology. Hepatology, 2014, 60, 1806-8.

Baumert TF, Zeuzem S. Overcoming the roadblocks in hepatitis C virus infection. J Hepatol., 2014, 61(1 Suppl), S1-2.

Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol., 2014, 61(1S):S79-S90.

Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses – recent progress and future impact. Curr. Opin. Virol., 2014, 4C, 58-65.

Zona L, Tawar RG, Zeisel MB, Xiao F, Schuster C, Lupberger J, Baumert TF. CD81-receptor associations – impact for hepatitis C virus entry and antiviral therapies. Viruses, 2014, 6, 875-92.

Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res., 2014, 104, 136-42.

Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. Hepatitis B and C: From Molecular virology to new antiviral therapies (part 1) Dtsch Med. Wochenschr., 2014, 139(13), 655-9.

Thimme R, Heim M, Baumert TF, Nassal M, Moradpour D. Hepatitis B and C: From Molecular virology to new antiviral therapies (part 2) Dtsch Med. Wochenschr., 2014, 139(15), 778-82.